Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09.

Slides:



Advertisements
Similar presentations
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Advertisements

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2015;148:100-7.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II Phase 3 Treatment Experienced Andreone.
Phase 2 of new ARVs BMS (maturation inhibitor)
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.
Clinical Aspects of Treatment with Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
IAC 2006 Abs# THLB0214 Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, as part of Combination ART in Treatment -Naïve HIV-1.
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
Hepatitis web study Hepatitis web study Daclatasvir-Asunaprevir-Beclabuvir in Genotype 1 Cirrhotics UNITY-2 Study Phase 3 Treatment-Naïve and Treatment-Experienced.
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,
1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results.
SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.
Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857) Mary McHale, Sam Abel, Deborah Russell, James Gallagher, Elna van der Ryst.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
Sulkowski MS, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/25/09.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.
Agenda  Update on Darunavir: Perry Mohammed  Update on Etravirine: Rekha Sinha  Update on TMC278: Peter Williams  Update on TMC207: Karel De Beule.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.
Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.
Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-
 Design  Objective –Difference in SVR ≥ 40% between the 2 groups, 99% power SOF + RBV Placebo Randomisation 3 : 1* Double blind HCV infection Genotype.
Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
Hepatitis web study Hepatitis web study Daclatasvir + Asunaprevir + Peg/RBV in Genotype 1 and 4 HALLMARK-QUAD Study Phase 3 Treatment-Experienced Jensen.
 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
Hepatitis web study Hepatitis web study Elbasvir + Grazoprevir in GT 1 and Chronic Renal Disease C-SURFER Phase 3 Treatment Naïve and Treatment Experienced.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Genotype 1 HCV infection Stable immunosuppressive therapy
Phase 3 Treatment Experienced
Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4
Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3
Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5
Phase 2 Treatment Naïve Injection Drug Use
Boceprevir in Treatment Naive SPRINT-2
Phase 3 Treatment Naïve HIV Coinfection
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Phase 3 Treatment-Naïve and Treatment-Experienced
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB
Phase 3 Treatment-Naïve and Treatment-Experienced
SOF/VEL ± RBV in genotype 3 with compensated cirrhosis
Telaprevir in Treatment Experienced GT-1 PROVE3
Presentation transcript:

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 1 SAFETY AND ANTIVIRAL ACTIVITY OF SCH ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS H. W. Reesink, J. F. Bergmann, J. de Bruijne, C. J. Weegink, J. van Lier, A. van Vliet, A. Keung, J. Li, E. O’Mara, M. A. Treitel, E. A. Hughes, H. L. A. Janssen, R. J. de Knegt 44th European Association for the Study of the Liver (EASL) Meeting Copenhagen, Denmark, April 24, 2009

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 2 Background: SCH   Mechanism-based inhibitor of the HCV NS3 serine protease   Replicon assay activity (HCV genotype 1b)   EC 50 = 20 nM, EC 90 = 40 nM   IFN-alfa–enhanced antiviral activity   Resistance profile of SCH   Similar to other protease inhibitors   Decreased resistance in combination with IFN- alfa in vitro   Primarily CYP3A4-mediated metabolism

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 3 Study Design   Treatment-naive and treatment-experienced patients with HCV genotype 1 infection   Two treatment periods in a fixed-sequence   Period 1 → Monotherapy for 7 days   Period 2 → Combination therapy with PEG-IFN alfa-2b for 14 days   Two doses explored (placebo-controlled)   800 mg TID SCH   400 mg BID SCH with ritonavir 200 mg BID (metabolic inhibition)

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 4 Study Design and Treatment Regimens 800 mg SCH TID Tx-Naive [n = 10] Tx-Experienced [ n = 10] 400 mg SCH BID mg RTV BID Tx-Naive [ n = 10] Tx-Experienced [ n = 11] >28-Day Washout 800 mg SCH TID + PEG-IFN alfa-2b (1.5  g/kg) >28-Day Washout 400 mg SCH BID mg RTV BID + PEG-IFN alfa-2b (1.5  g/kg) SOC Period 1Period 2 7 days14 days SOC = Standard of care, began after period 2 Serum HCV-RNA was determined using Roche COBAS TaqMan (v.2.0; LLQ = 25 IU/mL, LLD = 9.3 IU/mL) Randomized 4:1 (Active: Placebo) SCH dosed as amorphous suspension with food RTV = ritonavir

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 5 Baseline Characteristics Tx-Naive 800 mg TID (n = 10) Tx-Experienced 800 mg TID (n = 10) Tx-Naive 400 mg BID + RTV (n = 10) Tx-Experienced 400 mg BID + RTV (n = 11) Male, n (%)6 (60)7 (70)8 (80)10 (91) Race, n (%) Caucasian9 (90)8 (80) 7 (64) Black1 (10) 0 Other01 (10) 4 (36) Age, mean (SD), y51.1 (3.9)47.9 (7.4)43.6 (9.2)51.1 (7.2) Weight, mean (SD), kg73.5 (11.5)82.2 (12.5)79.4 (14.8)84.4 (13.2) BMI, mean (SD), kg/m (2.1) 27.8 (4.4) 25.3 (4.1) 26.3 (5.2) Patients receiving methadone, n (%) 1 (10)0 1 (9) Patients with hemophilia, n (%)001 (10)1 (9) Baseline HCV RNA, mean (SD) 4.8 x 10 6 (3.2 x 10 6 ) 6.3 x 10 6 (4.4 x 10 6 ) 3.8 x 10 6 (2.9 x 10 6 ) 4.3 x 10 6 (4.6 x 10 6 )

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 6 Safety AEs ≥10% During 7 Days of Monotherapy with SCH (± Ritonavir) Tx-Naive 800 mg TID (n = 8) Tx-Exper 800 mg TID (n = 8) Tx-Naive 400 mg BID+ RTV (n = 8) Tx-Exper 400 mg BID+ RTV (n = 9) Placebo (n = 4) Placebo+ RTV (n = 4) SUBJECTS REPORTING ANY AE, n 7*8*7*8*3* Headache304*400 Diarrhea Anorectal Discomfort4*21200 Nausea5*12010 Dizziness Somnolence4*20010 Abdominal Discomfort111003* Influenza-like Illness Abdominal Distension *Reported by ≥50% of patients

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 7 Safety AEs ≥10% During 14 Days of Combination Therapy SCH PEG-IFN alfa-2b (± Ritonavir) Tx-Naive 800 mg TID (n = 8) Tx-Exper 800 mg TID (n = 8) Tx-Naive 400 mg BID + RTV (n = 8) Tx-Exper 400 mg BID + RTV (n = 8) Placebo (n = 4) Placebo + RTV (n = 4) SUBJECTS REPORTING ANY AE, n 8* 3*4* Influenza-like Illness 8* 7* 3* Diarrhea2114*00 Headache Dyspepsia Injection Site Erythema Nausea *reported by ≥50% of patients *Reported by ≥50% of patients

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 8 SCH Overall Safety   Safe and well tolerated   No clinically significant changes in laboratory values, ECG recordings, or vital signs   Most AEs were mild or moderate in severity   One subject discontinued immediately after first dose because of intolerance to drug suspension   No SCH related SAEs   No deaths

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 9 Pharmacokinetics of SCH (± Ritonavir) at Steady-State in Combination With PEG-IFN alfa-2b Trough 11 x EC 90 Trough 61 x EC 90 t ½ ≈ 16 hours (+ RTV) t ½ ≈ 5 hours (alone) Hours After SCH Dose Plasma Concentration SCH (ng/mL) 400 mg BID + RTV 800 mg TID

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 10 SCH Monotherapy (± Ritonavir) Mean Change From Baseline in HCV RNA (Log 10 IU/mL) Morning Day Hours Mean Change in HCV RNA (Log 10 IU/mL) Placebo (n = 8) 800 mg TID Tx-Naive (n = 8) 800 mg TID Tx-Exper (n = 8) 400 mg BID/RTV Tx-Naive (n = 8) 400 mg BID/RTV Tx-Exper (n = 8)

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 11 SCH (± Ritonavir) + PEG-IFN alfa-2b Mean Change From Baseline in HCV RNA (Log 10 IU/mL) = PEG-IFN alfa-2b Dose Mean Change in HCV RNA (Log 10 IU/mL) Hours Placebo (n = 8) 800 mg TID Tx-Naive (n = 8) 800 mg TID Tx-Exper (n = 8) 400 mg BID/RTV Tx-Naive (n = 8) 400 mg BID/RTV Tx-Exper (n = 8) Morning Day 15

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 12 Resistance Analysis Individual Patient Plots of Treatment-Experienced Subjects Receiving SCH mg BID + Ritonavir Plasma HCV RNA (Log 10 IU/mL) = PEG-IFN alfa-2b Dose Hours Morning Day Resistant variants detected in these subjects at loci: V36, R155, A156

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 13 SCH : Antiviral Activity in Combination With PEG-IFN alfa-2b at Day 15 SCH (± RTV) + PEG-IFN alfa-2b Percent of Subjects With HCV RNA <LLQ (<25 IU/mL) Percent of Subjects With HCV RNA <LLD (<9.3 IU/mL) ExperiencedNaiveExperiencedNaive 800 mg TID SCH % (4/8) 75% (6/8) 0% (0/8) 38% (3/8) 400 mg BID SCH RTV 50% (4/8) 63% (5/8) 25% (2/8) 25% (2/8) Placebo 0% (0/4) 0% (0/4) 0% (0/4) 0% (0/4)

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 14 SCH Pharmacokinetic/Pharmacodynamic Relationship (Monotherapy ± Ritonavir) (6 × EC 90 ) (11 × EC 90 ) (41 × EC 90 ) (62 × EC 90 ) n = 7n = Median C min (ng/mL) by Quartile Mean Change in HCV-RNA Log 10 (lU/mL) on Day 7

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 15 Modeled SCH Tablet + Ritonavir Pharmacokinetics for Phase 2 Study ~12 x EC 90 ~16 x EC 90 Trough Values Time (hr) SCH mg QD/RTV SCH mg QD/RTV SCH mg BID/RTV ~8 x EC 90 Plasma Concentration SCH (ng/mL) Doses Tested in Phase 2

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 16 Preliminary Phase 2 Data in Naïve Patients SCH /Ritonavir + PEG-IFN alfa-2b/RBV (n=25) Once-Daily Dosing = PEG-IFN alfa-2b/RBV = 200 mg SCH QD mg RTV + PEG-IFN alfa-2b/RBV *Excludes one subject because of noncompliance with study medications Treatment Week 4 <LLQ = 19/20 (95%) <LLD = 15/20 (75%) , ,000 1,000,000 10,000, ,000, Days HCV RNA (Log 10 IU/mL) LLQ <25 IU/mL

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 17 Conclusions   SCH (± ritonavir ± PEG-IFN alfa-2b) was safe and well tolerated   No SCH related SAEs   SCH exhibited potent antiviral activity in both treatment-naive and treatment- experienced patients   Pharmacokinetic and pharmacodynamic modeling, as well as preliminary in-treatment antiviral data, support once-daily dosing of SCH with metabolic inhibition

Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09 18 Study Investigators and Colleagues AMC:SPRI: H. W. ReesinkE. A. Hughes J. de BruijneM. A. Treitel C. J. WeeginkE. O’Mara J. Li A. Keung EMC:PRA: H. L. A. JanssenJ. van Lier R. J. de KnegtA. van Vliet J. F. BergmannM. Ypey